ArticleCureus2026
The Price of Remission: Modeling the Total Financial Burden, Quality-of-Life Impairment, and Healthcare Dependence in Lupus Compared With Chimeric Antigen Receptor (CAR) T-cell Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease leading to chronic patient impairment, healthcare dependency, side effects from immunosuppressive drugs, and accumulation of medical costs. A single infusion of chimeric antigen receptor (CAR) T-cell therapy (CTCT) is currently expensive, approaching USD 500,000, but the lifetime costs of SLE, including medications, hospitalizations, travel, mental health effects, and lost income, may surpass this figure within years to over a decade, depending on disease severity. This study compares the medical, lifestyle, and quality-of-life financial burdens of SLE against a single CTCT infusion at a reference price of USD 500,000, suggesting that even at current prices, CTCT may be cost-effective for patients living with high to very severe disease activity. Beyond more quantifiable factors, the chance for complete remission and independence from the healthcare system could represent a major improvement in patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.